CARDIOVASCULAR
hamburger

HeartMate 3 LVAD has proven outcomes and an excellent safety profile

The HeartMate 3™ LVAD has been proven to help people with heart failure feel better and live longer.

81% survival rate at 2 years – similar to heart transplantation
79% of patients have reversal of heart failure symptoms – from NYHA Class IIIB/IV to I or II by 6 months


Results based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only.

Ability to walk more than 2 times farther3

Depiction of how far a person can walk on a football field. First icon demonstrating before HeartMate 3 LVAD therapy can walk 136m, and second icon demonstrating after HeartMate 3 LVAD therapy can walk 323m, which is over two times farther.

Risk and Adverse Event Information

There are serious adverse events associated with LVAD therapy. It is important to understand these risks and discuss them with your doctor.

Other than the risks normally associated with major surgery and having general anesthesia, the potential complications of having a HeartMate LVAD are listed here.

10% stroke 1% thrombosis after HeartMate 3 LVAD implant.

Results based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only.

HeartMate™ LVAD Information Center: 1-855-743-2786

Call us Monday through Friday, 7 A.M. - 7 P.M. Central time

If you call outside of these times, please leave a message and your call will be returned the next business day.

*82% 2-year survival for adult heart transplant patients between 2009 and 2015.

References

  1. Mehra, et al. Primary results of long-term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 LVAD implants. European Journal of Heart Failure. 2021. Doi:10.1002/ejhf.2211
  2. Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth Adult Heart Transplant Report-2018; Focus Theme: Multiorgan Transplantation. J Heart Lung Transplant. 2018;37:1155-1168.
  3. Mehra M, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Ventricular Assist Device-Final Report. N Engl J Med. 2019;380:1618-1627.
  4. Uriel N. Long-Term Burden of Hemocompatibility Related Adverse Events in the MOMENTUM 3 Trial: Final Analysis of the 1028 Patient Cohort. Presented at: The International Society for Heart & Lung Transplantation (ISHLT) Annual Meeting; April 4, 2019; Orlando, FL.
  5. Rogers JG, Pagani FD, Tatooles AJ, et al. Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med. 2017;376(5):451-460.
  6. Markham DW. Two-year Outcomes in the ENDURANCE Supplemental Trial. Presented at: American Heart Association (AHA) Annual Meeting; November 10, 2018; Chicago, IL.
INDICATIONS, SAFETY & WARNINGS

MAT-2108555 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2019 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.